GB Sciences Inc (GBLX)

[smallcapguru]

Wow, there is a lot of misinformation on this board. I am going to post facts from filings so there is no confusion. from the 10K: https://www.sec.gov/Archives/edgar/data/1165320/000144586618000685/gblx_10k.htm

GBLS retained Fenwick & West, a Silicon Valley based law firm focusing on life sciences and high technology companies with a nationally top-ranked intellectual property practice, to develop strategies for the protection of the Company's intellectual property. The following patents have been filed to date:


Three patent applications (USPTO & PCT)

10/2017_Cannabis-based Formulas to treat Neurodegenerative Disorders (PD, AD, dementia)

02/2018_Cannabis-based Formulas to treat Anti-Inflammatory Disorders (asthma, IBD, etc.)

05/2018_Myrcene-based Formulas to treat Heart Disorders & Pain


Four provisional patent applications (USPTO)

10/2016_Cannabis-based Formulas to treat Neurodegenerative Disorders (PD, AD, dementia)

02/2017_Cannabis-based Formulas to treat Anti-Inflammatory Disorders (asthma, IBD, etc.)

05/2017_Myrcene-based Formulas to treat Heart Disorders & Pain

05/2018_Cannabis-based Formula to Modulate Pain


Two licensed patents complete the GBLS portfolio:


Two licensed patents (USPTO & PCT)

03/2017_Licensed Cannabinoid Receptor-based Heart Disease Patent (approved)

10/2017_Exclusive Worldwide License on Time-Released Cannabinoid Nanoparticles (approved in Spain, applied in the US, Canada, and Europe)


GBLS is collecting research data and intends to file future patents on:


Future Patents in Discovery Phase

Triple-negative breast cancer therapies

Wound healing

HIV/AIDS adjunctive therapy without THC

HAND: HIV Associated Neurocognitive Disorder